Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy

Ablative radiotherapy is a highly efficient treatment modality for patients with metastatic prostate cancer (PCa). However, a subset of patients does not respond. Currently, this subgroup with bad prognosis cannot be identified before disease progression. We hypothesize that markers indicative of radioresistance, stemness and/or bone tropism may have a prognostic potential to identify patients profiting from metastases‐directed radiotherapy. Therefore, circulating tumor cells (CTCs) were analyzed in patients with metastatic PCa (n = 24) during radiotherapy with CellSearch, multicolor flow cytometry and imaging cytometry. Analysis of copy‐number alteration indicates a polyclonal CTC population that changes after radiotherapy. CTCs were found in 8 out of 24 patients (33.3%) and were associated with a shorter time to biochemical progression after radiotherapy. Whereas the total CTC count dropped after radiotherapy, a chemokine receptor CXCR4‐expressing subpopulation representing 28.6% of the total CTC population remained stable up to 3 months. At once, we observed higher chemokine CCL2 plasma concentrations and proinflammatory monocytes. Additional functional analyses demonstrated key roles of CXCR4 and CCL2 for cellular radiosensitivity, tumorigenicity and stem‐like potential in vitro and in vivo. Moreover, a high CXCR4 and CCL2 expression was found in bone metastasis biopsies of PCa patients. In summary, panCK+CXCR4+ CTCs may have a prognostic potential in patients with metastatic PCa treated with metastasis‐directed radiotherapy.

[1]  S. Löck,et al.  Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P) , 2022, Cancers.

[2]  P. Sarret,et al.  The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers , 2021, Cancer and Metastasis Reviews.

[3]  M. Krause,et al.  The distinct role of ALDH1A1 and ALDH1A3 in the regulation of prostate cancer metastases , 2021, bioRxiv.

[4]  M. Krause,et al.  Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response , 2021, Frontiers in Oncology.

[5]  Jin-hai Tang,et al.  Heterogeneity of CTC contributes to the organotropism of breast cancer. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  V. Khoo,et al.  Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials. , 2020, European urology oncology.

[7]  C. Lefebvre,et al.  An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. , 2020, European urology oncology.

[8]  Ash A. Alizadeh,et al.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.

[9]  N. Morrison,et al.  Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) Drives Activation of Bone Remodelling and Skeletal Metastasis , 2019, Current Osteoporosis Reports.

[10]  M. Jolly,et al.  Phenotypic heterogeneity in circulating tumor cells and its prognostic value in metastasis and overall survival , 2019, EBioMedicine.

[11]  N. Lawrentschuk,et al.  Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. , 2018, European urology.

[12]  N. Stoecklein,et al.  Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis , 2018, Clinical Cancer Research.

[13]  D. Lorente,et al.  Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Cooperberg,et al.  Identification and characterization of circulating tumor cells in post prostatectomy patients with localized high risk prostate cancer. , 2018 .

[15]  D. Haber,et al.  A conduit to metastasis: circulating tumor cell biology , 2017, Genes & development.

[16]  Amy R. Peck,et al.  Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth , 2017, Oncotarget.

[17]  T. Schlomm,et al.  Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients , 2016, Scientific Reports.

[18]  E. Heath,et al.  Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis , 2016, Molecular Cancer.

[19]  H. Scher,et al.  Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer , 2016, European urology.

[20]  K. Tabata,et al.  Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer , 2016, International journal of molecular sciences.

[21]  E. Schröck,et al.  An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells. , 2016, Cancer research.

[22]  James E. Verdone,et al.  Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters , 2016, Proceedings of the National Academy of Sciences.

[23]  P. Nilsson,et al.  Very low rate of circulating tumour cells (CTCs) in patients with PSA recurrence after radical prostatectomy referred to salvage radiotherapy , 2016, Acta oncologica.

[24]  M. Lock,et al.  The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy , 2015, Prostate Cancer and Prostatic Disease.

[25]  Hosung Jung,et al.  Localized CCR2 Activation in the Bone Marrow Niche Mobilizes Monocytes by Desensitizing CXCR4 , 2015, PloS one.

[26]  M. Wirth,et al.  Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. , 2015, Cancer research.

[27]  Sridhar Ramaswamy,et al.  Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.

[28]  S. Rosati,et al.  CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model , 2014, Clinical & Experimental Metastasis.

[29]  A. Dubrovska,et al.  CXCR4 as biomarker for radioresistant cancer stem cells , 2014, International journal of radiation biology.

[30]  A. Voigt,et al.  Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. , 2014, Cancer research.

[31]  Tim Holland-Letz,et al.  Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay , 2013, Nature Biotechnology.

[32]  B. Kong,et al.  Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1 , 2013, Cellular and Molecular Immunology.

[33]  P. Schultz,et al.  CXCR4 Expression in Prostate Cancer Progenitor Cells , 2012, PloS one.

[34]  Oscar Lin,et al.  Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer , 2009, Clinical Cancer Research.

[35]  Glenn Heller,et al.  Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[36]  Richard K Valicenti,et al.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Rogers,et al.  Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells , 2007, Molecular Cancer.

[38]  E. Messing,et al.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. , 2006, JAMA.

[39]  K. Pienta,et al.  CCL2 is a potent regulator of prostate cancer cell migration and proliferation. , 2006, Neoplasia.

[40]  T. Fehm,et al.  Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch® system and the CellCelector™ , 2017, Biotechnology progress.

[41]  R. Matkowski,et al.  Circulating Tumor , 2014 .